Search clinical trials for: CNTX-6970

Total 806 results

Centrexion Therapeutics

Completed

A Placebo-Controlled, Two-Part Study, Oral Dose to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CNTX-6970 in Healthy Subjects

Chronic Pain | Nociceptive Pain

United States
Ligand Pharmaceuticals

Completed

A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
Janssen Pharmaceutical K.K.

Completed

Safety, Pharmacokinetics, and Pharmacodynamics Study of Single Dose of CNTO 3649 in Healthy Adult Men and Multiple Doses of CNTO 3649 in Participants With Type 2 Diabetes Mellitus

Healthy | Diabetes Mellitus, Type 2

Japan
Ono Pharma USA Inc

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult Subjects

Healthy Adult Subjects

United States
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects

Healthy

Netherlands
Ono Pharma USA Inc

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult Subjects

Healthy Adult Subjects

United States
Ligand Pharmaceuticals
Medpace, Inc.

Completed

A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation

Type 2 Diabetes Mellitus (T2DM)

United States
Maurizio Fava, MD

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of CNTX-6970 in Subjects With Knee Osteoarthritis Pain.

Knee Osteoarthritis

United States
Idorsia Pharmaceuticals Ltd.

Completed

A Placebo-controlled Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects

Healthy

Germany
Pfizer

Completed

Study Evaluating the Effects of PSI-697 on Platelets in Subjects Who Smoke

Healthy
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Investigate the Pharmacokinetics of ACT-1014-6470 in Subjects With Severe Renal Impairment Compared to Control Subjects

Healthy

Germany
Edwards (Shanghai) Lifesciences Medical Supplies...

Completed

A Retrospective Study to Collect the Data From the Patients Who Had the Perimount Heart Valve Replacement Surgery in China During 2001 to 2007

Mitral Valve or Aortic Valve Replacement

China
Ligand Pharmaceuticals

Completed

Safety and Tolerability Study of Oral LGD-6972 for Type 2 Diabetes Mellitus (L6972-02)

Type 2 Diabetes Mellitus

United States
Jiangsu Simcere Pharmaceutical Co., Ltd.

Recruiting

A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors

Solid Tumor | Non Hodgkin Lymphoma

China
Centrexion Therapeutics

Completed

A Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)

Morton's Neuroma

United States
Centrexion Therapeutics

Completed

Safety and Tolerability of 4975 in the Treatment of Moderate to Severe Knee Pain Due to Osteoarthritis (OA)

Osteoarthritis of the Knee

United States
Centrexion Therapeutics

Completed

A Study to Evaluate the Efficacy and Safety of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)

Painful Intermetatarsal Neuroma (Morton's Neuroma)

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Study Evaluating PSI-697 in Patients With Scleritis

Scleritis
Eli Lilly and Company

Completed

A Study of Single and Repeated Doses of LY3556050 in Healthy Participants

Healthy

United States
Centrexion Therapeutics

Completed

A Clinical Study to Test Efficacy and Safety of Repeat Doses of CNTX-4975-05 in Patients With Osteoarthritis Knee Pain

Osteoarthritis, Knee

United States
Centrexion Therapeutics

Completed

A Study to Evaluate the Safety and Pharmacokinetics of CNTX-6016 in Healthy Subjects

Pain | Chronic Pain | Nociceptive Pain

United States
Pfizer

Completed

A Study To Investigate The Safety And Efficacy Of CP- 690,550 In Patients With Moderate And Severe Ulcerative Colitis.

Ulcerative Colitis

Brazil, Hungary, Belgium, Czech Republic, Italy, South Africa, Spain, United Kingdom, Sweden, Slovakia, Denmark, Poland, France, Chile, Israel, Mexico, Netherlands
Ligand Pharmaceuticals
Medpace, Inc.; Beckloff Associates, Inc.

Completed

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
University of Alabama at Birmingham

Recruiting

Peripheral Blood Flow Responses to Electromagnetic Energy

Exposure to Man-made Visible Light

United States
GE Healthcare

Completed

Demonstration of the "SPECT/CT System With CZT Detectors" Imaging Performance in a Clinical Setting

Cancer

Israel
Centrexion Therapeutics

Completed

Safety, Tolerability & Pharmacokinetics Study of CNTX-6016 in Healthy Subjects and Subjects With PDN

Painful Diabetic Neuropathy

United States
Janssen Research & Development, LLC

Completed

A Safety and Pharmacokinetics Study of CNTO 3157 in Healthy Japanese and Caucasian Participants

Healthy

United States
Vertex Pharmaceuticals Incorporated

Recruiting

A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) (Galileo)

Myotonic Dystrophy Type 1 (DM1)

Canada
Marval Pharma Ltd.

Terminated

Single Dose Safety, Tolerability and Pharmacokinetic Study of NCTX in Healthy Volunteers

Healthy Volunteers

United States
Centocor, Inc.

Completed

A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Centrexion Therapeutics

Completed

Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Chronic, Moderate to Severe Osteoarthritis Knee Pain

Osteoarthritis

United States
Janssen Inc.

Completed

A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis (X-PLORE)

Psoriasis

United States, Poland, Canada, Belgium, Germany
Centrexion Therapeutics

Completed

A Phase 3 Efficacy and Safety Study of Intra-articular CNTX-4975-05 (Capsaicin) vs Placebo in Subjects With OA Knee Pain

Osteoarthritis, Knee

United States
Janssen-Cilag International NV

Completed

A Safety, Tolerability, Pharmacokinetics, and Immunogenicity Study of CNTO 6785 in Healthy Volunteers

Healthy

Belgium
Massachusetts General Hospital
EMD Serono

Completed

M6620 (VX-970) in Selected Solid Tumors

Osteosarcoma | Solid Tumor | Leiomyosarcoma

United States
Centocor, Inc.

Terminated

A Study to Evaluate the Safety of CNTO 2476 in Patients With Advanced Retinitis Pigmentosa

Retinitis Pigmentosa

United States
Janssen Pharmaceutical K.K.

Withdrawn

Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)

Macular Degeneration | Geographic Atrophy | Visual Acuity

Japan
Janssen Research & Development, LLC

Completed

A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Known as Stroke)

Infarction | Ischemia | Stroke

United States
Calcilytix Therapeutics, Inc., a BridgeBio company

Completed

Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1

Autosomal Dominant Hypocalcemia (ADH)

United States
Janssen Research & Development, LLC

Completed

A Study of Subcutaneously-administered Guselkumab Delivered by 3 Different Devices in Healthy Participants

Healthy

United States, Germany
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Pustular Psoriasis

Japan
Janssen Research & Development, LLC

Completed

A Single Ascending Dose Study in Healthy Participants and Multiple Ascending Dose Study of CNTO 7160 in Participants With Asthma and Participants With Atopic Dermatitis

Healthy | Asthma | Atopic Dermatitis

Germany, Belgium
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Effectiveness and Safety of CNTO6785 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Poland, Germany, Taiwan, Malaysia, Korea, Republic of, Czech Republic, Russian Federation, Hungary
Centocor Research & Development, Inc.

Completed

A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous
Centocor, Inc.

Completed

A Study of the Safety and How the Body Affects a Drug (CNTO 1959) in Healthy Volunteers and in Patients With Psoriasis

Psoriasis

United States
Neurotech Pharmaceuticals
The Lowy Medical Research Institute Limited

Completed

Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2

Macular Telangiectasia Type 2

United States, Australia
Neurotech Pharmaceuticals

Completed

A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa

Retinitis Pigmentosa

United States
Jeffrey L Goldberg

Completed

NT-501 CNTF Implant for Glaucoma: Safety, Neuroprotection and Neuroenhancement

Glaucoma, Primary Open Angle

United States
Centocor, Inc.

Completed

A Phase 1 Study of CNTO 3157 in Healthy Volunteers and Patients With Asthma

Asthma

Germany, United Kingdom, Belgium
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States

HIV Infections

United States

3

Subscribe